Submicroscopic subtelomeric aberrations in Chinese patients with unexplained developmental delay/mental retardation

Ye Wu†1, Taoyun Ji†1, Jingmin Wang1, Jing Xiao2, Huifang Wang1,3, Jie Li1,3, Zhijie Gao1,4, Yanling Yang1, Bin Cai5, Liwen Wang2, Zhongshu Zhou6, Lili Tian7, Xiaozhu Wang8, Nan Zhong8, Jiong Qin1, Xiru Wu*1 and Yuwu Jiang*1

Abstract

Background: Subtelomeric imbalance is widely accepted as related to developmental delay/mental retardation (DD/MR). Fine mapping of aberrations in gene-enriched subtelomeric regions provides essential clues for localizing critical regions, and provides a strategy for identifying new candidate genes. To date, no large-scale study has been conducted on subtelomeric aberrations in DD/MR patients in mainland China.

Methods: This study included 451 Chinese children with moderate to severe clinically unexplained DD/MR. The subtelomere-MLPA (multiplex ligation dependent probe amplification) and Affymetrix human SNP array 6.0 were used to determine the subtelomeric copy number variations. The exact size and the breakpoint of each identified aberration were well defined.

Results: The submicroscopic subtelomeric aberrations were identified in 23 patients, with a detection rate of 5.1%. 16 patients had simple deletions, 2 had simple duplications and 5 with both deletions and duplications. The deletions involved 14 different subtelomeric regions (1p, 2p, 4p, 6p, 7p, 7q, 8p, 9p, 10p, 11q, 14q, 15q, 16p and 22q), and duplications involved 7 subtelomeric regions (3q, 4p, 6q, 7p, 8p, 12p and 22q). Of all the subtelomeric aberrations found in Chinese subjects, the most common was 4p16.3 deletion. The sizes of the deletions varied from 0.6 Mb to 12 Mb, with 5-143 genes inside. Duplicated regions were 0.26 Mb to 11 Mb, with 6-202 genes inside. In this study, four deleted subtelomeric regions and one duplicated region were smaller than any previously reported, specifically the deletions in 11q25, 8p23.3, 7q36.3, 14q32.33, and the duplication in 22q13. Candidate genes inside each region were proposed.

Conclusions: Submicroscopic subtelomeric aberrations were detected in 5.1% of Chinese children with clinically unexplained DD/MR. Four deleted subtelomeric regions and one duplicated region found in this study were smaller than any previously reported, which will be helpful for further defining the candidate dosage sensitive gene associated with DD/MR.

Background

Developmental delay/mental retardation (DD/MR) occurs in 1%-3% of the general population [1,2]. MR is defined as a significant impairment of both cognitive (IQ < 70) and social adaptive functions, with onset before 18 years of age. MR can not be diagnosed until the child is older than 5 years, when the intelligence measurements are reliable. For children younger than 5 years, the term “DD” is usually used. The etiological diagnosis is challenging, because diverse genetic and environmental factors may contribute to its pathogenesis [3,4]. It is estimated that 25%-50% of moderate to profound DD/MR is resulted from genetic etiology [5]. G-banding karyotyping is a routine clinical test for DD/MR patients, and the reported frequency with which it detects microscopic chromosomal aberrations varies between 9%-36% [6]. However, microscopic techniques cannot detect interstitial or terminal subtelomeric microdeletions and microduplications [4]. Progress in molecular cytogenetic
techniques, such as fluorescent in situ hybridization (FISH), multiplex ligation dependent probe amplification (MLPA) and array comparative genomic hybridization (aCGH), has resulted in detection of submicroscopic subtelomeric rearrangements in approximately 5% (0-23%) of DD/MR patients [7-14].

Subtelomeric regions are usually enriched for genes, and are more susceptible to aberrant rearrangements than other chromosomal regions [15,16]. Subtelomeric imbalance is widely accepted as leading to DD/MR or multiple congenital anomalies (MCA), although the exact cause-and-effect relationship has not been well defined [17-24]. The clinical consequences are probably determined by the location and kind of the rearrangement, such as deletions or duplications, as well as the size of the aberrations, including the numbers and function of the genes involved [20]. These aberrant regions are likely to contain undiscovered candidate genes associated with DD/MR. Fine mapping of aberrant subtelomeric regions to determine the critical regions and genes has become a new strategy for identifying novel candidate genes for DD/MR [25].

In 2007, 11,820,000 people in mainland China had an intellectual disability, of whom 954,000 were younger than 6 years of age. To date, no large-scale study has been conducted on subtelomeric aberrations in Chinese DD/MR patients. Here we report the investigation of 451 Chinese children with clinically unexplained DD/MR, using subtelomere-MLPA and Affymetrix human SNP array 6.0. Subtelomeric aberrations were identified, their exact sizes were defined, and possible candidate genes are proposed.

Methods
Patients
Patients with unexplained DD/MR were defined as those without etiological diagnosis after thorough clinical evaluations, and were included based on the following criteria: 1) moderate to severe DD/MR (IQ < 55, assessed with Gesell Developmental Schedules or Wechsler intelligence scale for children); 2) definite exclusion of perinatal brain injury; 3) no history of toxification, hypoxia, central nervous system infection and cranial trauma; 4) normal routine karyotyping; 5) no evidence of recognizable inherited metabolic disorder or specific neurodegenerative disorders by brain imaging and blood/urinary metabolic screening; 6) negative for mutations in the FMR1 gene for male patients; 7) negative for typical clinical features of Rett syndrome for female patients.

All 451 subjects were Chinese children from the Department of Pediatrics in Peking University First Hospital and Department of Neurology in Beijing Children's Hospital, recruited from 2006-2008, and informed consent was obtained. Genomic DNA was extracted from peripheral blood for each index patient and his or her parents. The research was approved by Medical Ethics Committee of Peking University First Hospital.

MLPA for screening of subtelomeric rearrangements
A specifically designed set of probes for testing subtelomeric imbalances in the SALSA P070 and P036B human telomere test kits (MRC-Holland, Amsterdam, Netherlands; http://www.mrc-holland.com) was used. For each patient with consistent positive results from both kits, their parents' samples were tested.

The MLPA mix contained probes for all subtelomeric regions except the short arms of the acrocentric chromosomes (13p, 14p, 15p, 21p and 22p), for which, probe recognition sequences were on the q arm, in one of the genes just proximal to the telomeric repeats. Sequences detected by two probes mixes were different from each other. MLPA analysis was performed following the manufacturer's instruction. Amplification products were identified and quantified by capillary electrophoresis on an ABI 3100 genetic analyzer. The fluorescent signal strength of the PCR products was determined using Genemarker1.5 software. For each patient, the normalized peak pattern of each subtelomeric region was divided by the average peak pattern of all samples (n > 10) in the same experiment. The resulting values were approximately 1.0 for wild type peaks, <0.75 for deletions, and >1.3 for duplications.

Affymetrix human SNP array 6.0 assay
To confirm and accurately define the exact size of each subtelomeric aberration region found by MLPA, Affymetrix genome-wide human SNP array 6.0 was used. Each array has 1,800,000 genetic markers, including more than 906,600 single nucleotide polymorphisms (SNPs) and more than 946,000 probes for detecting copy number variations (CNVs). The high density of the probes across the genome and combination of a SNP array with aCGH probes in a single chip enabled the accurate definition of the size of each aberrant region.

Digestion, ligation, PCR, labeling, hybridization and scanning were performed following standard protocols. Partek software (version 6.3) was used for the analysis of CNVs. Duplicated or deleted regions were determined by Hidden Markov Model (HMM) calculation. Involvement of at least three contiguous probe sets was required, and when a copy number calculated by HMM as <1.5 was considered a deletion, while >2.5 was considered a duplication.

Results
Screening of subtelomeric rearrangements with MLPA revealed an abnormality in 34 of 451 patients. Deletion in a single region was found in 22 patients (15pter del in 5;
4pter del in 4; 13pter del in 3; 11qter del in 2; 9pter del in 2; and deletion in 1pter, 7qter, 8pter, 15qter, 16pter and 22qter in 1 patient each). Deletions in two different subtelomeric regions were identified in 2 patients (13pter del + 22qter del, 14qter del + 17qter del). Duplication in single subtelomeric region was found in 3 patients (3qter dup in 2; 22qter dup in 1). 7 patients were found to have both a deletion and duplication (8pter del + 7pter dup in 2; 2pter del + 4pter dup; 10pter del + 6qter dup; 9pter del + 19pter dup; 7pter del + 12pter dup; and 6pter del + 8pter dup). Subsequent MLPA assay for parents showed that all rearrangements were absent in the parents.

To further confirm and accurately define the exact size of each subtelomeric aberration detected by MLPA, subsequent assay with Affymetrix genome-wide human SNP array 6.0 was performed on 24 patients. Because the MLPA probe recognition sequences for 13p and 15p are actually on the q arm, and do not represent the subtelomeric regions, 8/34 subjects with 15pter del or 13pter del were not studied further. Array analysis was also not performed for an additional 2 of the 34, specifically with 8pter del + 7pter dup, and 9pter del + 19pter dup, due to insufficiency of DNA samples.

Subtelomeric copy number aberrations were confirmed in 23 of 24 patients, with a final detection rate of 5.1% (23/451), of which 16 (69.6%) were found to have simple deletions, 2 (8.7%) had a simple duplication and 5 (21.7%) had complex rearrangements. The deletions involved 14 different subtelomeric regions (1p, 2p, 4p, 6p, 7p, 7q, 8p, 9p, 10p, 11q, 14q, 15q, 16p and 22q), and duplications involved 7 subtelomeric regions (3q, 4p, 6q, 7q, 8p, 12p and 22q). In 4p, 7p, 8p and 22q, both subtelomeric deletions and duplications were detected. The size of the deletions varied from 0.6 Mb to 12 Mb, with 5-143 genes inside. Duplicated regions were 0.26 Mb to 11 Mb, with 6-202 genes inside.

Clinical features of patients and the results from MLPA and Array are summarized in Table 1 and Table 2.

Discussion
Since the identification of submicroscopic subtelomeric rearrangements as a cause of idiopathic MR in 1995, testing for subtelomeric abnormalities has become an important clinical evaluation step for the etiological diagnosis of unexplained DD/MR in Western countries [1,4,26-29]. This is the first large-scale study carried out on submicroscopic subtelomeric aberrations in Chinese patients.

Subtelomeric aberrations identified in Chinese patients
Obtaining an accurate prevalence for subtelomeric aberrations in idiopathic DD/MR is difficult [7]. Using MLPA followed by array analysis, we achieved a detection rate of 5.1% (23/451) in Chinese patients with moderate to severe clinically unexplained DD/MR. This was comparable to most previous reports on other populations. We identified several well-known terminal deletion syndromes in 4p16.3, 1p36, 22q13.3 and terminal 11q. Rare chromosomal terminal aberrations were also found, including deletions in 8p23.3, 7q36.3, 15q26.2-q26.3 and 14q32.3, as well as 22q13 duplication. Of all the subtelomeric aberrations found in Chinese subjects, the most common was 4p16.3 deletion (Wolf-Hirschhorn syndrome), identified in 4/23. In this study, four deleted subtelomeric regions and one duplicated region were smaller than any other previously reported, specifically the deletions in 11q25, 8p23.3, 7q36.3, 14q32.33, and the duplication in 22q13. This information will be helpful for further defining the critical regions that contain candidate DD/MR-associated genes.

Subtelomeric aberrations smaller than previous reports
11q terminal deletion
We found 2 patients (patient 419 and 1591) with an 11q terminal deletion, which is reported to present with DD, short stature, congenital heart disease(CHD), thrombocytopenia, genitourinary anomalies, pyloric stenosis, and ophthalmologic defects. The critical regions of the deletion might correlate with specific clinical phenotypes. Grossfeld et al defined critical regions for 14 individual phenotypes [30]. The smallest critical region (6.8 Mb) they reported extended from D11S1351 (located in 11q24.2) to the telomere, and was associated with four phenotypes, including Paris-Trousseau platelet disorder, undescended testes, pyloric stenosis, and MR. Coldren et al proposed two loci in distal 11q related to global and selective deficits in neurocognitive function [31]. The smallest deletion 11q terminus was reported by Bernacciak in 2008, which was 5 Mb in size [32]. In our study, patient 419 had a 4.11 Mb deletion in 11q25, spanning from 130.33 Mb to 134.45 Mb (figure 1), which is smaller than any other previous reports. The patient had DD and facial dysmorphism including thin upper lip, V-shaped mouth, micrognathia and low-set ears, but without platelet disorder, undescended testes or pyloric stenosis. Thus, the critical region underlying the phenotype of DD/MR in 11q terminal deletion disorder is probably in the most distal part, within 4.11 Mb of the telomere. The deleted region contains 20 genes, with 14 expressed in human brain. SNX19 (sorting nexin-19), THYN1 (thymocyte nuclear protein 1), OPCML (opioid-binding protein/cell adhesion molecule-like), VPS26B (vacuolar protein sorting 26, yeast, homolog of B), NCAPD3 (non-SMC condensing II complex subunit D3) and NTM (neurotransmin) might be candidate genes, and the encoded proteins are associated with intracellular trafficking, phosphoinositide binding, mitotic chromosome assembly and segregation, outgrowth of neurites, and apoptosis.
8p23.3 deletion
Microscopically visible distal 8p deletions are associated with growth and mental impairment, minor facial anomalies, congenital heart defects, and behavioral problems. Submicroscopic subtelomeric 8p deletion is uncommon, with only a few reported cases [33]. de Vries BB et al reported two cousins with 5.1 Mb of terminal 8p deletion, who presented with mild MR, normal facial appearance, normocephaly and behavioral problems such as unsocialized conduct disorder [34]. We found 1 patient (339) with a very small deletion in terminal 8p, 2.06 Mb to the telomere (in 8p23.3). This one-year-old girl presented with DD, microcephaly and minor facial dysmorphism. Thus, we can define the critical region underlying DD/MR in subtelomeric 8p deletion within the distal 2.05 Mb. This area contains 28 genes, and 12 are known to be expressed in human brain. Among them, CLN8 and DLGAP2 (discs large-associated protein 2) might be candidate genes. CLN8 is involved in lipid synthesis and transportation, and mutations are related to neuronal ceroid lipofuscinoses (NCL), an autosomal recessive neurodegenerative disorder. The product of DLGAP2 is a membrane-associated guanylate kinases localized at postsynaptic densities in neuronal cells. This kinase is in a family of signaling molecules found at various submembrane domains, and may play a role in the molecular organization of synapses and in neuronal cell signaling.

7q terminal deletion
A few cases were found to have terminal 7q deletions. The 7q36-qter deletion is usually associated with DD/MR, low birth weight, growth retardation, abnormal skull shape, and some facial dysmorphism like nose malformation, hypertelorism, and ear malformation [35]. This study reports a patient with the smallest deletion (1.53 Mb) detected in terminal 7q to date. She was 2 years of age, and presented with DD, microcephaly, low hair line, ocular hypertelorism, ptosis, and prominent ear and hand malformations. The deleted region was in 7q36.3, spanning from 157.29 Mb to 158.82 Mb, which contains only seven genes. PTPRN2 (protein tyrosine phosphatase, receptor type N), NCAPG2 (leucine zipper protein 5), VIPR2 (vasoactive intestinal peptide receptor 2),

| Clinical Characteristics                              | Patient with subtelomeric imbalance confirmed by MLPA and Array (23 patients) N (%) | Patients without sub-telomeric aberrations (428 patients) N (%) |
|-------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Gender, M/F                                           | 10/13                                                                            | 300/128                                                          |
| Age                                                   | 1.9 y (6 m-7 y 10 m)                                                             | 4.2 y (6 m-29 y)                                                 |
| Seizure                                               | 3 (13.0)                                                                         | 117 (27.3)                                                      |
| Autistic features                                     | 0 (0.0)                                                                          | 0 (0.0)                                                         |
| Family history of DD/MR                               | 3 (13.0)                                                                         | 64 (15.0)                                                       |
| Maternal history of miscarriages                      | 3 (13.0)                                                                         | 9 (2.1)                                                         |
| Microcephaly                                          | 11 (47.8)                                                                        | 104 (24.3)                                                      |
| Macrocephaly                                          | 0 (0.0)                                                                          | 17 (4.0)                                                        |
| Low birth weight                                      | 7 (30.4)                                                                         | 32 (7.5)                                                        |
| Growth delay                                          | 5 (21.7)                                                                         | 104 (24.3)                                                      |
| Minor facial and non-facial dysmorphism               | 18 (78.3)                                                                        | 217 (50.7)                                                      |
| Other congenital abnormalities                        | 9 (39.1)                                                                         | 63 (14.7)                                                       |
Table 2: Clinical findings, MLPA and Affymetrix SNP array 6.0 results in 24 patients underwent array assay

| Patient ID | MLPA | Affymetrix human SNP 6.0 Array | Clinical findings |
|------------|------|--------------------------------|-------------------|
|            | Gain /loss | Chromosome band | Start (Mb) | End (Mb) | Size (Mb) | Number of genes | Gender | Age | Seizure | Autistic feature | Dysmorphism or other congenital abnormalities | Microcephaly | Low birth weight | Growth delay | Family history |
| 1472       | 1pter- loss | 1p36.33-p36.32 | 0.83 | 3.12 | 2.29 | 74 | F | 7 y 10 m | / | / | hirsutism, hypertelorism, clinodactyly | / | + | / | / |
| 1115       | 4pter- loss | 4p16.3-p16.1 | 0.057 | 9.83 | 9.77 | 138 | M | 6 m | / | / | Greek warrior helmet appearance of the nose, cleft lip/palate, polymicrogyria, thin corpus callosum | + | + | / | / |
| 1483       | 4pter- loss | 4p16.3-p16.2 | 0.057 | 3.38 | 3.32 | 58 | F | 9 m | / | / | Greek warrior helmet appearance of the nose, micrognathia, high-arched palate, dermatoglyphic anomalies | + | + | + | / |
| 1834       | 4pter- loss | 4p16.3-p16.1 | 0.057 | 9.82 | 9.77 | 138 | F | 1 y 3 m | + | / | Greek warrior helmet appearance of the nose, micrognathia, prominent ear, cleft palate, calcification of kidneys, hepatic hemangioma, CHD, dysplasia of atlas | + | + | + | / |
| 1980       | 4pter- loss | 4p16.3-p16.2 | 0.056 | 4.12 | 4.07 | 67 | F | 1 y 2 m | + | / | Greek warrior helmet appearance of the nose, high-arched palate, prominent ear | + | + | + | + |
| 1971       | 7qter- loss | 7q36.3 | 157.29 | 158.82 | 1.53 | 7 | F | 2 y 1 m | / | / | low hair line, hypertelorism, ptosis, prominent ears, hand anomalies | + | / | / | / |
| 339  | 8pter- loss 8p23.3 | 0.021 | 2.067 | 2.05 | 28 | F | 1 y | / | / | hypertelorism, long philtrum, malformed ears | + | / | / | / |
| 1467 | 9pter- loss 9p24.3 | 0.67  | 1.54  | 0.87 | 5  | F | 2 y 11 m | / | / | / | / | / | / |
| 2268 | 9pter- loss 9p24.3-24.1 | 0.19  | 7.01  | 6.82 | 48 | M | 3 y | / | / | flat nasal bridge, prominent ears, dermatoglyphic anomalies | / | / | / | / |
| 419  | 11qpter- loss 11q25 | 130.33| 134.45| 4.12 | 20 | M | 7 m | / | / | long philtrum, low set ears, micrognathia, thin upper lip, V-shaped mouth | / | / | / | / |
| 1591 | 11qpter - loss 11q23.3-q25 | 119.98| 132.81| 12.82| 143| F | 2 y 5 m | / | / | light hair color, Hypertelorism, high-arched palate, dermatoglyphic anomalies, CHD | / | / | / | / |
| 1309 | 15qpter- loss 15q26.2-q26.3 | 92.79 | 100.29| 7.50 | 48 | M | 11 m | / | / | flat nasal bridge, small palpebral fissure, hypertelorism, dermatoglyphic anomalies, clinodactyly, inguinal hernia, polycytic kidney | / | / | / | + | |
| 2689 | 16pter- loss 16p13.3 | 0.00077| 1.28  | 1.28 | 69 | F | 6 y | / | / | high-arched palate, hypertelorism, prominent ears, thin corpus callosum | / | / | / | / |
| 2498 | 22qpter- loss 22q13.32-13.33 | 47.43 | 49.41 | 1.97 | 41 | F | 3 y | / | / | / | / | / | / | + | / |
| 1038 | 3qter+ gain 3q29 | 194.37 | 199.38 | 5.01 | 67 | M | 5 y 10 m | / | / | hirsutism, prominent ears, dermatoglyphic anomalies, CHD, cryptorchidism | + | / | / | / |
| Patient ID | Chromosome | qter Status | Band | Age | Gender | Clinical Findings | MLPA | Affymetrix SNP Array 6.0 Results |
|------------|-------------|-------------|------|-----|---------|------------------|------|-----------------------------|
| 1518       | 3qter       | +           |      | M   | 5 y 11 m | + hirsutism, prominent ears, sparse teeth |      |                            |
| 1729       | 22qter      | gain        | 22q13.33 | 49.32 | F | 7 m | + flat nasal bridge, small palpebral fissure, prominent ears, dermatoglyphic anomalies, CHD |      |                            |
| 1704       | 14qter      | loss        | 14q32.33 | 104.53 | M | 4 y 6 m | + |                          |
| 390        | 13pter      |             |      | M | 1 y | + thin corpus callosum |      |                            |
| 1947       | 10pter      | loss        | 10p15.3-15.1 | 0.062 | M | 9 m | + hypertelorism, flat nasal bridge, micrognathia, CHD |      |                            |
| 1711       | 8pter       | loss        | 8p23.3 | 0.16 | M | 4 y 10 m | + long philtrum |      |                            |
| 2126       | 6pter       | loss        | 6p25.3 | 0.33 | M | 3 y 3 m | + thin corpus callosum |      |                            |
| 17qter     |              |             |      | M | 4 y 6 m | + |                          |
| 17qter     |              |             |      | M | 4 y 6 m | + |                          |
| 22qter     |              | loss        | 22q13.31-q13.33 | 46.90 | F | 8 m | + hypertelorism, flat nasal bridge |      |                            |
| 4pter      |              | gain        | 4p16.3 | 0.15 | F | 8 m | + |                         |
| 6pter      |              | loss        | 6p25.3 | 0.33 | M | 3 y 3 m | + thin corpus callosum |      |                            |
| 8pter      |              | gain        | 8p23.3 | 0.021 | M | 3 y 3 m | + |                          |
| 8pter      |              | gain        | 8p23.3 | 0.021 | M | 3 y 3 m | + |                          |
Table 2: Clinical findings, MLPA and Affymetrix SNP array 6.0 results in 24 patients underwent array assay (Continued)

| Patient | 7pter- loss 7p22.3 | 12pter+ gain 12p13.33-13.2 | 0.26 2.01 1.76 23 | F | 1 y 7 m | / | / | ptosis, long philtrum, downturned corners of the mouth | / | / | / | / |
|---------|--------------------|----------------------------|-------------------|---|----------|---|---|------------------------------------------------|---|---|---|---|

+ = positive, / = negative
FAM62B (family with sequence similarity 62) and WDR60 (WD repeat domain 60) are expressed in human brain. PTPRN2 and NCAPG2 might be candidates. The protein encoded by PTPRN2 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. NCAPG2 is a non-SMC (structural maintenance of chromosome) subunit that defines condensin II. Condensin complexes I and II play essential roles in mitotic chromosome assembly and segregation. It’s reported that microcephalin/MCPH1 is one of the causative genes responsible for the autosomal recessive disorder primary microcephaly. Patients with this disease present with mental retardation and dramatic reduction in head size, and cells derived from these patients contain abnormally condensed chromosomes. More recently, MCPH1 has been implicated in the cellular response to DNA damage, although its exact mechanism remains unclear. In 2008, Wood et al identified condensin-II as a major MCPH1-interacting protein. MCPH1 and condensin II interact in vivo, mediated by the CAPG2 subunit of condensin II [36].

14q32.33 deletion
We identified one patient (1704) with a very small deletion in 14q32.33. Terminal deletions of the 14q are rare. The common clinical features shared by patients with 14qter deletions include mild to moderate DD/MR, microcephaly, high forehead with lateral hypertrichosis, broad nasal bridge, long and broad philtrum, thin upper lip, high arched palate, single palmar crease, and hypotonia [37]. Seizures are absent in most patients with 14qter deletions, but were reported in one case with a 3.2 Mb terminal deletion in 14q32.32 [38]. Early onset intractable seizures usually present in ring 14 rather than 14qter deletions [39]. Patient 1704, a 4-year-old boy, presented with moderate DD and seizures, with no dysmorphism or congenital abnormalities. The terminal 14q deletion found in this patient is the smallest reported to date, spanning from 104.53 Mb to 105.21 Mb, for only 0.68 Mb. This region contains 24 genes, with 15 expressed in human brain. MTA1 (metastasis associated protein), BRF1 (transcription initiation factor IIIB isoform3), NUDT14 (nucleoside diphosphate-linked moiety × motif 14) and JAG2 (jagged 2 isoform a precursor) might be candidate genes for DD/MR. They are involved in regulation of transcription, cell proliferation, glycosylation and intercellular signal transduction.

22q13.3 deletion and duplication
We found both deletions and duplications in terminal 22q (patient 390 with 22q13.31-13.33 deletion, patient 2498 with 22q13.32-13.33 deletion and patient 1729 with 22q13.33 duplication). 22q13.3 deletion syndrome is a recognizable malformation syndrome associated with DD, hypotonia, delayed or absent speech, autistic-like behavior, normal to accelerated growth and dysmorphic faces with epicanthal folds, large/dysplastic ears, pointed chin, dolichocephaly and ptosis [40,41]. Anderlid et al refined the critical area to 100 kb in 22q13.33, which contains three genes, ProSAP2 (SHANK3), ACR (acrosin precursor) and RABL2B (RAB, member of RAS oncogene family-like 2B) [42]. SHANK3 is a good candidate gene, as it is preferentially expressed in the cerebral cortex and cerebellum, and encodes a scaffolding protein involved in the postsynaptic density of excitatory synapses. De novo deletions and mutations of SHANK3 have been found in individuals with autism [43-47]. The deleted region in patient 390 was 2.68 Mb in size, extending from 4.69 Mb to 4.96 Mb, containing 46 genes, including the reported critical area. The patient had low birth weight, normal growth and a thin corpus callosum. He was only one year old, so delayed or absent speech or autistic behavior could not be determined. With 1.97 Mb of deletion in 22q, patient 2498 showed absent speech at 3 years of age. The 22q13 duplication is not common, with only a few cases reported. Some clinical features, including intra-
uterine growth retardation, CHD and other dysmorphism were described [48]. Patient 1729 had some facial dysmorphism, CHD, microcephaly and growth delay. She had a 258 kb duplication, spanning from 4.93 Mb to 4.96 Mb. To our knowledge, this is the smallest reported duplication in the terminal region of 22q. Seven genes reside in the duplicated area, which contains SHANK3, ACR, RABL2B, MAPK8IP2 (mitogen-activated protein kinase 8 interacting) and ARSA (arylsulfatase A, isoform b). Therefore deletion as well as duplication of critical genes like SHANK3, are likely to be associated with common phenotypes like DD/MR, since DD/MR is shared by all patients with 22q13.33 deletion or duplication.

Subtelomeric duplications
We found pure terminal duplications in 2/451 subjects (0.4%). Subtelomeric pure microduplications are an infrequent cause of MR/MCA with a frequency of approximately 0.5% [49]. We identified 22qter and 3qter microduplications. Patient 1038 showed common features of the dup (3q) syndrome including hirsutism, microcephaly, low-set ears, malformation of hands, cryptorchidism and CHD [50]. He had recurrent afebrile seizures since 3 months of age. A 5.0 Mb duplication in 3q29 (from 194.37 Mb to 199.38 Mb) was detected in this patient, containing 67 genes. Our finding supports the observation made by Battaglia et al. [51], who suggested that the critical region underlying the phenotype of dup 3q is in 3q29.

Common phenotypes in submicroscopic subtelomeric aberrations
For most subtelomeric rearrangements, a specific phenotype has not been defined, making recognition and selection of patients for such tests challenging in clinical practice. Some common clinical features might be shared by patients with various subtelomeric abnormalities. A five-item checklist of clinical features for pre-selection of patients for subtelomeric rearrangements was proposed by de Vries BB et al, including: 1) family history of MR; 2) prenatal onset of growth retardation; 3) postnatal growth abnormalities; 4) at least two facial dysmorphic features; and 5) at least one non-facial dysmorphic feature and/or congenital abnormality [52]. In our study, for patients with moderate to severe DD/MR with a normal karyotype, those with subtelomeric rearrangements (n = 23) had a higher percentage of microcephaly (47.8% vs. 24.3%), low birth weight (30.4% vs. 7.5%), maternal history of miscarriage (13.0% vs. 2.1%), facial/non-facial dysmorphism (78.3% vs. 50.7%) and other congenital abnormalities (39.1% vs. 14.7%), than those without subtelomeric rearrangement (table 1). Therefore, these might be common features shared by most DD/MR patients with submicroscopic subtelomeric aberrations. Nonetheless, some patients, like patient 1467, with an 874 kb deletion in 9p24.3, only presented with DD and microcephaly. And patient 1704, with a deletion in 14q32.33, had no clinically recognizable dysmorphism.

Conclusions
This large-scale study reports the detection of submicroscopic subtelomeric aberrations in Chinese patients with DD/MR for the first time. Subtelomeric rearrangements were found in 5.1%. Although benign subtelomeric variations exist [53], most de novo subtelomeric aberrations are considered pathogenic. Further observations of a larger number of patients with similar submicroscopic subtelomeric abnormalities may lead to the recognition of specific phenotypes, and will be helpful in the clinical etiologic diagnosis of DD/MR. More important, fine mapping of aberrations in gene-enriched subtelomeric regions provides essential clues for localizing critical regions, and provides a strategy for identifying new candidate genes associated with DD/MR.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
YW participated in writing the manuscript and patients’ recruitment. YJ and XRW had the primary responsibility for protocol development and writing the manuscript. TJ participated in writing the manuscript and carried out the laboratory work concerning the MLPA and data analysis. JW, HW, JL, ZG, XzW and NZ participated in laboratory work concerning the Affymetrix SNP 6.0 array and data analysis. All authors read and approved the manuscript.

Acknowledgements
We are grateful to the patients’ families. This work was funded by Chinese National Key Research Project "973", (2007CB5119004) and Natural Science Foundation of Beijing (7081004).

Author Details
1Department of Pediatrics, Peking University First Hospital, Beijing, China,
2Department of Neurology, Beijing Children’s Hospital, Capital Medical University, Beijing, China, 3Shanxi Medical University, Taiyuan, China, 4Department of Neurology, Capital Institute of Pediatrics Affiliated Children’s Hospital, Beijing, China, 5CapitalBio Corporation-National Engineering Research Center for Beijing Biochip Technology, Beijing, China, 6Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China, 7Department of Pediatrics, Xuanwu Hospital, Capital Medical University, Beijing, China and 8Peking University Center of Medical Genetics, Beijing, China

Received: 26 December 2009 Accepted: 11 May 2010

Published: 11 May 2010

References
1. Shaffer LG, American College of Medical Genetics Professional Practice and Guidelines Committee: American college of medical genetics guideline on the cytogenetic evaluation of the individual with developmental delay or mental retardation. Genet Med 2005, 7:650-654.
2. Leonard H, Wen X: The epidemiology of mental retardation: challenges and opportunities in the new millennium, Ment Retard Dev Disabil Res Rev 2002, 8:117-34.
3. Ropers HH: Genetics of intellectual disability. Curr Opin Genet Dev 2008, 18:241-250.

http://www.biomedcentral.com/1471-2350/11/72
4. Moechsljer B, Shevell M. American Academy of Pediatrics Committee on Genetics. Clinical genetic evaluation of the child with mental retardation. Pediatrics. 2006;117:2934-6.
5. Hunter AG. Outcome of routine assessment of patients with mental retardation in a genetic clinic. Am J Med Genet 2000, 90:60-68.
6. Scheppers-Tijdink GA, Cufi LM, Wiegens A, Kleczkowska A, Frins JP. A systematic cytogenetic study of a population of 1170 mentally retarded and/or behaviourally disturbed patients including fragile X screening. The Hopielsberg experience. J Genet Hum 1988, 36:425-46.
7. Xu J, Chen Z. Advances in molecular cytogenetics for the evaluation of mental retardation. Am J Med Genet C Semin Med Genet 2003, 117C:15-24.
8. Aradhya S, Manning MA, Splendore A, Cherry AM: Whole-genome array-CGH identifies novel contiguous gene deletions and duplications associated with developmental delay, mental retardation, and dysmorphic features. Am J Med Genet A 2007, 143A:1431-41.
9. Edelmann L, Hirschhorn K. Clinical utility of array CGH for the detection of chromosomal imbalances associated with mental retardation and multiple congenital anomalies. Ann N Y Acad Sci 2009, 1151:157-66.
10. Shao L, Shaw CA, Lu YJ, Sahoo T, Baccino CA, Lalani SR, Stankiewicz P, Yatsenko SA, Li Y, Neill S, Pursey AN, Chinault AC, Panul A, Beaudet AL, Lupski JR, Cheung SW. Identification of chromosome abnormalities in subtelomeric regions by microarray analysis: a study of 3,580 cases. Am J Med Genet A 2008, 146A:2242-51.
11. Rooms L, Reyniers E, van Luijk R, Scheers S, Wauters J, Ceulemans B, Ende J. Identification of chromosome abnormalities in subtelomeric regions by microarray analysis: a study of 3,580 cases. Am J Med Genet A 2008, 146A:2242-51.
12. Northrop EL, Ren H, Bruno DL, McGhee JD, Coffa J, Schouten J, Choo KH, Slater HR. Detection of cryptic subtelomeric chromosome abnormalities and identification of anonymous chromatin using a quantitative multiplex ligation-dependent probe amplification (MLPA) assay. Hum Mutat 2005, 26:477-86.
13. Baronacci A, Filivesi F, Capuccia A, Coccì G, Franchi F, Sensi A, Battaglia P, Aiello V, Calabozzi E. FISH screening for subtelomeric rearrangements in 219 patients with idiopathic mental retardation and normal karyotype. Eur J Med Genet 2005, 48:388-96.
14. Knight SJ, Regan R, Nicod A, Horsley SW, Kearney L, Homfray T, Winter RM, Bolton P, Flint J. Subtle chromosomal rearrangements in children with unexplained mental retardation. Lancet 1999, 354:1676-81.
15. Saccone S, De Sario A, Della Valle G, Bernardi G. The highest gene concentrations in the human genome are in telomeric bands of metaphase chromosomes. Proc Natl Acad Sci USA 1992, 89:4913-7.
16. Brown J, Saracoğlu K, Uhír S, Speicher MR, Ellis R, Kearney L. Subtelomeric chromosome rearrangements are detected using an innovative 12-color FISH screening protocol. Hum Genet 2001, 109:497-501.
17. Moechsljer MB. Medical genetics diagnostic evaluation of the child with global developmental delay or intellectual disability. Curr Opin Neurol 2008, 21:117-22.
18. Di Bella MA, Calì F, Seidita G, Mirisola M, Ragusa A, Ragalmuto A, Galesi O, Lo Giudice C, van Rijn A, van Bokhoven H. Disruption of the gene Euchromatin Histone Methyl Transf erase1 (Eu-HMTase1) is associated with the 9q34 subtelomeric deletion syndrome. J Med Genet 2005, 42:299-306.
19. Battaglia A, Carey JC. Diagnostic evaluation of developmental delay/mental retardation: An overview. Am J Med Genet C Semin Med Genet 2003, 117C:13-4.
20. Flint J, Wilkie AO, Buckle VJ, Winter RM, Holland AJ, McDermid HE. The detection of subtelomeric chromosomal rearrangements in idiopathic mental retardation. Nat Genet 1995, 9:132-40.
21. Basel-Vanaglate L. Clinical approaches to genetic mental retardation. Isr Med Assoc J 2008, 10:21-6.
22. de Vries BB, Beijani BA, Sour M, Rorem EA, Hall N, Shaffer LG. Array comparative genomic hybridization in global developmental delay. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1101-8.
23. Grossfeld PD, Mattina T, Ia Z, Favier R, Jones KL, Cotter F, Jones C. The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet A 2004, 129A:5-11.
24. Malek CD, Lai Z, Shaghp P, Rossi E, Gieldewski CS, Zuffardi O, Mattina T, IVY DD, Curfs LM, Mattson SN, Riley EP, Treier M, Grossfeld PD. Chromosomal microarray mapping suggests a role for BSK and Neurogranin in neurocognitive and behavioral defects in the 11q terminal deletion disorder (Jacobsen syndrome). Neurogenetics 2009, 10:89-95.
25. Bernacki J, Szczepkowski K, Derwińska K, Wiktoria-Jozwikowicz B, Bocian E, Sasiadek MM, Makowska I, Stankiewicz P, Smigiel R, Smigiel R, Smigiel R. Molecular-cytogenetic evaluation of a family with partial Jacobsen syndrome associated with developmental delay, mental retardation and behavioral problems caused by a familial t(8;20)(p23;p13) translocation. Orphanet J Rare Dis 2009, 4:36.
26. Roos A, Rudnik-Schöneborn S, Eggermann K, Eggermann T, Sendereck J, Schwantitz G, Zeres K, Schuler HM. Submicroscopic unbalanced translocation resulting in del(1p)dup(1q31)3q12 detected by subtelomere FISH. Hum Genet 2006, 89:179-186.
27. Hellas-Rodziewicz Z, Bocian E, Stankiewicz P, Obersztyn E, Kostyk E, Jakubów-Durska K, Kutzkiowa-Kadziernicka A, Mazurczak T. Subtelomeric rearrangements detected by FISH in three of 33 families with idiopathic mental retardation and minor physical anomalies. J Med Genet 2002, 39:5-3.
28. Shaw-Smith CA, Prezelin BP, Rickman L, Rio M, Willatt L, Fiegler H, Firth H, Sanlaville D, Winter R, Colleaux L, Bobrow M, Carter NP. Microarray based comparative genomic hybridization (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. J Med Genet 2004, 41:241-8.
29. Vissers LE, de Vries BB, Ooigoave K, Janssen IM, Feuth T, Choy CO, Straatman H, Velt W van der, Huys EH, van Rijk A, Smeets D, van Ravenswaaij-Arts CM, Knoers NV, Burgt I van der, de Jong PJ, Brunner HG, van Kessel AG, Schoenmakers EF, Veltman JA. Array-based comparative genomic hybridization for the genome-wide detection of submicroscopic chromosomal abnormalities. Am J Hum Genet 2003, 73:1261-70.
30. Shevell M. Global developmental delay and mental retardation or intellectual disability: conceptualization, evaluation, and etiology. Pediatr Clin North Am 2008, 55:1071-84.
31. de Vries BB, Pfurdtt R, Bokhoven H, Van Kessel AG, Schoenmakers EF, Brunner HG, Veltman JA. Diagnostic genome profiling in mental retardation. Am J Hum Genet 2005, 77:506-16.
32. Kleefstra T, Smidt M, Banning Nl, Oudakker AR, Van Esch H, de Brouwer AP, Nillesen W, Sierman MA, Hamel BC, de Bruin O, Frins JP, Yntema HG, Brunner HG, de Vries BB, Van Bokhoven H. Disruption of the gene Euchromatin Histone Methyl Transf erase1 (Eu-HMTase1) is associated with the 9q34 subtelomeric deletion syndrome. J Med Genet 2005, 42:299-306.
speech and language delay. *Am J Med Genet C Semin Med Genet* 2007, 145C:393-8.

42. Anderlid BM, Schoumans J, Annerén G, Tapia-Paez I, Dumanski J, Blennow E, Nordenskjöld M: FISH-mapping of a 100-kb terminal 22q13 deletion. *Hum Genet* 2002, 110:439-43.

43. Marshall CR, Noor A, Vincent JB, Lionet AC, Feuk L, Skaug J, Shago M, Moesnner R, Pinto D, Ren Y, Thiruvahindrapuham D, Fiebig A, Schreiber S, Friedman J, Ketelaars CE, Vos YJ, Ficcioglu C, Kirkpatrick S, Nicolson R, Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat D, Weksberg R, Thompson A, Vardy C, Grohve V, Luscombe S, Baatjes R, Zwaigenbaum L, Roberts W, Fernandez B, Sztamnari P, Scherler SW: Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet* 2008, 82:477-488.

44. Durand CM, Betancur C, Bocckmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsäter H, Sponheimer E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Pax P, Bierth E, Rogé B, Héron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat Genet* 2007, 39:25-27.

45. Wilson HL, Wong AC, Shaw SR, Tse WY, Stapleton GA, Phelan MC, Hu S, Marshall J, McDermid HE: Molecular characterization of the 22q13 deletion syndrome supports the role of haplinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. *J Med Genet* 2003, 40:575-584.

46. Gauthier J, Spiegelman D, Piton A, Lafrenière RG, Laurent S, St-Onge J, Lapointe L, Hamdan FF, Carrette P, Mottron L, Fombonne E, Joober R, Leboyer M, Bourgeron T: Novel de novo SHANK3 mutation in autistic patients. *Am J Med Genet B Neuropsychiatr Genet* 2009, 150B:421-4.

47. Sykes NH, Toma C, Wilson N, Volpi EV, Sousa I, Pagnamenta AT, Tancredi R, Battaglia A, Maestrelli E, Bailey J, Monaco AP, International Molecular Genetic Study of Autism Consortium (IMGSAC): Copy number variation and association analysis of SHANK3 as a candidate gene for autism in the IMGSAC collection. *Eur J Hum Genet* 2009, 17:1347-53.

48. Pramparo T, de Gregori M, Gimelli S, Ciccone R, Chiaraluce D, Leibl T, Pellacani S, Masi G, Brovedani P, Zuffardi O, Guerini R: A 7 Mb duplication at 22q13 in a girl with bipolar disorder and hippocampal malformation. *Am J Med Genet A 2008, 146A:1754-60.

49. Fender J, Spiegelman D, Pito A, Lafrenière RG, Laurent S, St-Onge J, Lapointe L, Hamdan FF, Mottron L, Fombonne E, Joober R, Mercurio E, Drapeau P, Rouleau GA: Pure subtelomeric microduplications as a cause of mental retardation. *Clin Genet* 2007, 72:362-8.

50. Faas BH, De Vries BB, Van Es-Van Gaal J, Merks G, Draaisma JM, Smeets DF: A new case of dup (3q) syndrome due to a pure duplication of 3qter. *Clin Genet* 2002, 62:315-20.

51. Battaglia A, Novelli A, Ceccarini C, Carey J: Familial complex 3q;10q rearrangement unravelled by subtelomeric FISH analysis. *Am J Med Genet* 2006, 140A:144-150.

52. de Vries BB, White SM, Knight SJ, Regan R, Homfray T, Young ID, Super M, McKewon C, Split M, Quanrell OW, Trainer AH, Niemeyer MF, Malcolm S, Fender J, Hurst JA, Winter RM: Clinical studies on submicroscopic subtelomeric rearrangements: a checklist. *J Med Genet* 2001, 38:145-50.

53. Balkova I, Menten B, de Ravel T, Le Caing C, Tienpont B, Urbina M, Doco-Fenzy M, de Rademaker M, Mortier G, Kooy F, Ende J, van der, Devriendt K, Fryns JP, Speleman F, Vermeersch J: Subtelomeric imbalances in phenotypically normal individuals. *Hum Mutat* 2007, 28:958-67.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/11/72/prepub

doi: 10.1186/1471-2350-11-72

Cite this article as: Wu et al., Submicroscopic subtelomeric aberrations in Chinese patients with unexplained developmental delay/mental retardation. *BMC Medical Genetics* 2010, 11:72